1. INTRODUCTION
1.1. KEY TAKE AWAYS
1.2. REPORT DESCRIPTION
1.3. MARKETS COVERED
1.4. STAKEHOLDERS
2. SUMMARY
3. MARKET OVERVIEW
3.1. EVOLUTION OF DRUG-DEVICE COMBINATION
3.2. DRIVING FACTORS ANALYSIS FOR DRUG-DEVICE COMBINATION MARKET
3.3. DRIVERS
3.3.1. INCREASED EFFICIENCY
3.3.2. EXPLOITING EXISTING TECHNOLOGIES
3.3.3. ACCELERATED APPROVAL PROCESS
3.3.4. MEDICAL INSURANCE COVERAGE
3.3.5. RISING AWARENESS
3.4. RESTRAINTS
3.4.1. ISSUES INVOLVED IN CROSS INDUSTRY PARTNERSHIPS
3.4.2. DRUG-DEVICE COMBINATION PRODUCTS ARE EXPENSIVE
3.4.3. JURISDICTION ISSUES
3.4.4. FEAR OF POSSIBLE SIDE-EFFECTS
3.5. OPPORTUNITIES
3.5.1. REDUCTION IN INVESTMENT COSTS
3.5.2. STREAMLINING ISSUES IN PARTNERSHIPS
3.5.3. REDUCTION IN THE OVERALL COST OF TREATMENT
3.5.4. MARKET PARTICIPATION BY SMALLER COMPANIES
4. DRUG-DEVICE COMBINATION PRODUCTS
4.1. ANTIMICROBIAL CATHETER
4.1.1. DRIVERS
4.1.1.1. Reduced incidences of infection in intensive care units
4.1.1.2. Over all cost reduction
4.1.1.3. Certain catheters are prone to infections
4.1.1.4. Reimbursement issues
4.1.1.5. Presence of big players in the antimicrobial catheters market
4.1.1.6. Awareness of antimicrobial agents used for coating on the catheters
4.1.1.7. Demand unaffected by the economic downturn
4.1.2. RESTRAINTS
4.1.2.1. Price constraints
4.1.2.2. Lack of awareness in developing countries
4.1.3. KEY PLAYERS & THEIR RECENT DEVELOPMENTS
4.1.4. UROLOGICAL CATHETERS
4.1.4.1. Drivers
4.1.4.1.1. Prevention of several nosocomial infections
4.1.4.1.2. Beneficial for women and baby boomers
4.1.4.1.3. Reduced health care costs
4.1.4.1.4. Increased applications
4.1.4.2. Restraints
4.1.4.2.1. Alternatives to prolonged catherization
4.1.4.2.2. Reimbursement issues
4.1.4.2.3. Key P layers and Their Recent Developments
4.1.4.3. Dialysis catheter
4.1.4.3.1. Key players and their recent developments:
4.1.4.3.2. Hemodialysis catheters
4.1.4.3.3. Peritoneal catheters
4.1.4.3.3.1. Drivers
4.1.4.4. Urinary catheters
4.1.4.4.1. Drivers
4.1.4.4.2. Key players and their recent developments
4.1.4.4.3. Indwelling catheters
4.1.4.4.3.1. Drivers
4.1.4.4.3.2. Restraints
4.1.4.4.3.3. Key players and their recent developments
4.1.4.4.4. External catheter
4.1.5. CARDIOVASCULAR CATHETERS
4.1.5.1. Drivers
4.1.5.1.1. Indispensability associated with these catheters
4.1.5.1.2. Suitable in emergency operations
4.1.5.1.3. Rising number of obesity aiding the growth of the
procedures that use these products
4.1.5.1.4. Interventional procedures have better success ratio
4.1.5.2. Restraints
4.1.5.2.1. Usage avoided due to high cost and subsequent
reimbursement issue
4.1.5.2.2. Incidence of infections due to the use of non antimicrobial coated catheter not known
4.1.5.2.3. Competition from new technologies and devices
4.1.5.3. Opportunities
4.1.5.3.1. Awareness of surgeons
4.1.5.3.2. Resolving reimbursement structure
4.1.5.3.3. Decreasing prices
4.1.6. OXIMETRY CATHETERS
4.1.6.1. Drivers
4.1.6.1.1. Reduction in catheter related blood stream infections
4.1.6.1.2. Prolonged fight against micro organisms
4.1.6.1.3. Overall cost of hospitalization will go down
4.1.6.1.4. Popularity of uncoated variant
4.1.6.2. Key players and their recent developments
4.1.7. THERMODILUTION CATHETERS
4.1.7.1. Drivers
4.1.7.1.1. Fatal infections are avoided
4.1.7.1.2. Increased usage likely in near future
4.1.7.1.3. Increasing complications of the heart
4.1.7.2. Restraints
4.1.7.2.1. Uncoated thermodilution catheters are cheaper
4.1.7.2.2. Fear of resistance from microorganism strains
4.1.7.2.3. Innovations in pharmaceutical therapies
4.1.8. WOUND DRAINAGE CATHETERS
4.1.8.1. Drivers
4.1.8.1.1. Useful in several surgeries
4.1.8.1.2. Protection from wide variety of micro organisms
4.1.8.1.3. Elimination of the risk of nosocomial infections on the wound sites
4.1.8.2. Restraints
4.1.8.2.1. Proper handling required
4.2. ADVANCED WOUND CARE PRODUCTS
4.2.1. DRIVERS
4.2.1.1. Multiple advantages over conventional wound care products
4.2.1.2. Supports healing process of the skin
4.2.1.3. Advanced gel based products accelerate healing process
4.2.1.4. Prevention of bacterial colonization on sutures
4.2.1.5. Reduction in the cost of hospitalization
4.2.1.6. Less frequent change of dressings required
4.2.2. RESTRAINTS
4.2.2.1. Lack of product differentiation leading to price wars
4.2.2.2. Minimally invasive surgeries are stunting the demand of wound care products
4.2.3. OPPORTUNITIES
4.2.3.1. Focus on research
4.2.3.2. Raise awareness of the care providers
4.2.3.3. Specially developed wound dressing products
4.2.4. KEY PLAYERS AND THEIR RECENT DEVELOPMENTS
4.2.5. ANTIBIOTIC WOUND CARE
4.2.5.1. Drivers
4.2.5.1.1. Treatment is conducive for wide range of patients
4.2.5.1.2. Low risk of infections as silver is an ingredient in the product
4.2.5.1.3. Nanotechnology paves the way for improved formulations
4.2.5.1.4. Target patients
4.2.5.2. Restraints
4.2.5.2.1. Cost constraint
4.2.5.2.2. Reimbursement issues
4.2.5.3. Opportunities
4.2.5.3.1. Rising awareness about the risk of infections
4.2.5.3.2. Edification of medical practitioners
4.2.5.3.3. Ageing baby boomers
4.2.5.4. Key players and their recent developments
4.3. BONE GRAFT SUBSTITUTES
4.3.1. DRIVERS
4.3.1.1. Shortage of donors
4.3.1.2. Substitutes satisfying ideal properties of bone
4.3.1.3. Virtual elimination of the risk of infection
4.3.1.4. Improved life expectancy
4.3.1.5. Increasing need for orthopedic procedures
4.3.2. RESTRAINTS
4.3.2.1. ‘One size fits all’ approach not possible
4.3.2.2. Procedure not affordable for all
4.3.3. KEY PLAYERS AND THEIR RECENT DEVELOPMENTS
4.3.4. CERAMIC BASED BONE GRAFT SUBSTITUTE
4.3.4.1. Drivers
4.3.4.1.1. Most popular bone graft substitutes
4.3.4.1.2. Compatibility with new technology
4.3.4.1.3. Risk of transference of fatal diseases eliminated
4.3.4.1.4. Availability in various forms gives wider choice for applications
4.3.4.1.5. Close proximity of composition to natural bone
4.3.4.2. Restraints
4.3.4.2.1. Stand alone ceramic products are brittle
4.3.4.2.2. Application limited to non load bearing sites
4.3.4.2.3. Newer technology stunting the stand alone ceramics market
4.3.4.3. Ceramic based bone graft substitutes mixed with calcium phosphate
4.3.4.3.1. Drivers
4.3.4.3.2. Restraints
4.3.4.3.3. Opportunities
4.3.4.3.4. Key players and their recent developments
4.3.5. ALLOGRAFT BASED BONE GRAFT SUBSTITUTES
4.3.5.1. Drivers
4.3.5.1.1. Totally natural enables faster healing
4.3.5.1.2. Wide array of choice for various applications
4.3.5.1.3. Extraction of DBM helps in spine fusion
4.3.5.1.4. Localized application of DBM enables faster healing
4.3.5.2. Restraints
4.3.5.2.1. Risk of disease diffusion not entirely eliminated
4.3.5.2.2. Success depends on the site of application
4.3.5.3. Opportunities
4.3.5.3.1. Wider adoption of new technology
4.3.5.4. Key players and their recent developments
4.3.6. FACTOR BASED BONE GRAFT SUBSTITUTE
4.3.6.1. Drivers
4.3.6.1.1. Cellular activity made possible in the bone
4.3.6.1.2. Removal of risks of toxicity
4.3.6.1.3. Availability of supporting technology
4.3.6.2. Restraints
4.3.6.2.1. Several products yet to receive marketing approval
4.3.6.2.2. No guaranteed results
4.3.6.2.3. Production process incurs high cost
4.3.6.3. Opportunities
4.3.6.3.1. Effectiveness in treating spinal fusion
4.3.6.3.2. More ‘factors’ to boost the market
4.3.6.4. Key players and their recent developments
4.3.7. CELL BASED BONE GRAFT SUBSTITUTES
4.3.7.1. Drivers
4.3.7.1.1. Most adaptive to human body among all bone graft substitute variants
4.3.7.1.3. Faster healing
4.3.7.1.4. Simple process of extraction
4.3.7.2. Restraints
4.3.7.2.1. Limited results in practice
4.3.7.2.2. Supporting technologies not available
4.3.7.2.3. Several regulatory issues yet to be resolved
4.3.7.3. Opportunities
4.3.7.3.1. Successful results
4.3.7.3.2. Advancement in supporting technologies
4.3.7.4. Key players and their recent developments
4.4. ANTIBIOTIC BONE CEMENTS
4.4.1. DRIVERS
4.4.1.1. Faster healing because of localized treatment
4.4.1.2. Prevention of infections
4.4.2. RESTRAINTS
4.4.2.1. Low bacterial resistance
4.4.2.2. Prone to allergic reactions
4.4.2.3. Expensive
4.4.3. KEY PLAYERS AND THEIR RECENT DEVELOPMENTS
4.5. DRUG ELUTING STENTS
4.5.1. DRIVERS
4.5.1.1. Increased life expectancy
4.5.1.2. Interventional procedures have higher effectiveness
4.5.1.3. Global acceptance of drug eluting stent technologies
4.5.1.4. Reduces the need for repeat procedures
4.5.2. RESTRAINTS
4.5.2.1. Risk of clots for some patients
4.5.2.2. Adoption of better cholesterol fighting drugs
4.5.2.3. Bare metal stents cheaper than drug eluting stents
4.5.3. OPPORTUNITIES
4.5.3.1. FDA’s support for drug eluting stents
4.5.3.2. New generation drug eluting stent
4.5.4. KEY PLAYERS AND THEIR RECENT DEVELOPMENTS
4.5.5. CORONARY STENTS
4.5.5.1. Drivers
4.5.5.1.1. Growing popularity of minimally invasive surgery
4.5.5.1.2. Prevention of reblockage
4.5.5.1.3. Reduced instances of deaths by heart attacks
4.5.5.1.4. Diminished need for repeated procedures
4.5.5.1.5. Obesity and other factors driving cardiac related issues
4.5.5.2. Restraints
4.5.5.2.1. Limited applications
4.5.5.2.2. ‘Off-label’ applications
4.5.5.2.3. Increased restrictions following controversy
4.5.5.2.4. Possibility of side effects due to drug therapy following surgery
4.5.5.3. Opportunities
4.5.5.3.1. Possibility of increased applications
4.5.5.3.2. Supporting technology reduces the risk of in-stent late thrombosis
4.5.5.4. Key players and their recent developments
4.5.6. PERIPHERAL VASCULAR STENT
4.5.6.1. Drivers
4.5.6.1.1. Alleviation of pain in the aged population
4.5.6.1.2. Severe results are eliminated
4.5.6.1.3. Prevalence of cigarette smoking acts as a driver
4.5.6.2. Restraints
4.5.6.2.1. Limited data available due to ignorance of the disease
4.5.6.2.2. Lack of awareness of physicians
4.5.6.3. Key players and their recent developments
4.6. PHOTODYNAMIC THERAPY
4.6.1. DRIVERS
4.6.1.1. Localized treatment increases the effect of the therapy
4.6.1.2. Less time gap between consumption of drug and light treatment
4.6.1.3. Advantages over antibiotics
4.6.1.4. Treatment is inexpensive
4.6.2. RESTRAINTS
4.6.2.1. Competition from traditional treatments
4.6.2.2. Side effects
4.6.3. OPPORTUNITIES
4.6.3.1. Advanced research will help to treat larger solid tumors
4.6.3.2. Promising field of non invasive anti tumor therapy
4.6.4. KEY PLAYERS AND THEIR RECENT DEVELOPMENTS
4.6.5. AMINOLEVULINIC ACID
4.6.5.1. Drivers
4.6.5.1.1. Accuracy in treatment
4.6.5.1.2. Increase in potential size
4.6.5.1.3. Increased potential in selected markets
4.6.5.1.4. Minimally invasive nature is attractive
4.6.5.1.5. New avenues of treatment
4.6.5.1.6. Cheaper than other alternatives
4.6.5.2. Restraints
4.6.5.2.1. Application limited to selected areas of the body
4.6.5.2.2. Prone to photosensitivity
4.6.5.2.3. Other more efficient treatments are available
4.6.5.3. Opportunities
4.6.5.3.1. Application limited to certain geographical areas
4.6.5.3.2. Innovation will lead to better results
4.6.6. PORFIMER SODIUM
4.6.6.1. Drivers
4.6.6.1.1. A popular form of treatment
4.6.6.1.2. No long term side effects
4.6.6.1.3. Number of applications
4.6.6.1.4. Treatment suitable for patients who do not qualify for other treatments
4.6.6.2. Restraints
4.6.6.2.1. Treatment is not independent
4.6.6.2.2. Success depends upon the stage of the disease
4.6.6.2.3. Treatment eliminates extensive forms of cancer
4.6.6.2.4. Presence of side effects
4.6.6.3. Key players and their recent developments
4.6.7. VERTEPORFIN
4.6.7.1. Drivers
4.6.7.1.1. Treats macular degeneration of the wet type
4.6.7.1.2. Targeted treatment is effective on diseased area
4.6.7.2. Restraints
4.6.7.2.1. Repeated procedures required
4.6.7.2.2. New inventions in drug therapy
4.6.7.2.3. Possible risk
4.6.7.3. Opportunities
4.6.7.3.1. Side effects associated with drug therapy
4.6.7.3.2. New developments eliminate the need for repeat procedures
4.7. STEROID ELUTING ELECTRODES
4.7.1. DRIVERS
4.7.1.1. Increasing demand for pacemakers and ICDs
4.7.1.2. Continuously monitors the heart
4.7.1.3. Increased longevity
4.7.2. RESTRAINTS
4.7.2.1. Advantages of non steroid eluting electrodes
4.7.2.2. Monopoly by a few companies
4.7.3. KEY PLAYERS AND THEIR RECENT DEVELOPMENTS
4.7.4. IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
4.7.4.1. Drivers
4.7.4.1.1. Prevention of inflammation
4.7.4.1.2. Improved diagnosis of cardiac problem
4.7.4.2. Restraints
4.7.4.2.1. Limited choice in product variety
4.7.4.2.2. Restrained promotion about their effectiveness
4.7.5. DEEP BRAIN STIMULATOR
4.7.5.1. Drivers
4.7.5.1.1. Treatment provides therapeutic benefits
4.7.5.1.2. Varied applications
4.7.5.2. Restraints
4.7.5.2.1. Fear of side effects
4.8. CLOSED LOOP GLUCOSE MONITOR AND INSULIN PUMP
4.8.1. DRIVERS
4.8.1.1. Minimal invasiveness leads to convenience
4.8.1.2. Hassle free diabetes management
4.8.1.3. Treatment made reliable
4.8.1.4. A killer disease
4.8.1.5. Monitoring of diabetes combating therapies
4.8.1.6. Monitoring of extreme levels of glucose
4.8.1.7. Insurance coverage
4.8.2. RESTRAINTS
4.8.2.1. Human intervention necessary
4.8.2.2. The combination product expensive
4.8.2.3. New technology
4.8.3. OPPORTUNITIES
4.8.3.1. Under penetration of the product in the U.S.
4.8.3.2. Further development of technology
4.8.4. KEY PLAYERS AND THEIR RECENT DEVELOPMENTS
5. DRUG-DEVICE COMBINATION APPLICATION
5.1. CARDIOVASCULAR TREATMENT
5.1.1. DRIVERS
5.1.1.1. Provide better treatment
5.1.1.2. Increasing number of cardiovascular treatments
5.1.1.3. Increased comfort to the elderly
5.1.1.4. Diabetes patients with cardiovascular problems
5.1.2. RESTRAINTS
5.1.2.1. Restriction enforced by FDA
5.1.2.2. Post surgery medication adds up to the cost
5.1.2.3. Prevention of cardiovascular diseases
5.1.3. CORONARY ANGIOPLASTY
5.1.3.1. Drivers
5.1.3.1.1. Reduced risk of sudden heart attacks
5.1.3.1.2. Treatment independent of economic situation
5.1.3.2. Restraints
5.1.3.2.1. Not recommended for angina
5.1.3.2.2. Expensive nature of treatment
5.1.4. TACHYCARDIA MANAGEMENT
5.1.4.1. Drivers
5.1.4.1.1. Reduced chances of heart failure
5.1.4.1.2. Diagnosis has opened up new avenues
5.1.4.2. Restraints
5.1.4.2.1. Unknown potential market size
5.1.4.2.2. Lack of awareness
5.1.5. PEDIATRIC BRADYCARDIA
5.1.5.1. Drivers
5.1.5.2. Restraints
5.2. NON CARDIOVASCULAR TREATMENTS
5.2.1. DRIVERS
5.2.1.1. Several new treatments for non cardiovascular diseases
5.2.1.2. Issue of reimbursement
5.2.1.3. Untapped markets
5.2.1.4. Reap full potential of present technologies
5.2.2. RESTRAINTS
5.2.2.1. Partnership issues
5.2.2.2. Rising popularity of alternative therapies
5.2.2.3. Underlying cause of disease not known
5.2.3. PERIPHERAL ARTERIAL DISEASE (PAD)
5.2.3.1. Symptoms of the disease are often confused with general problems of old age.
5.2.4. INTRAVASCULAR ACCESS
5.2.4.1. Drivers
5.2.4.1.1. Indispensable in modern day medical imstitutions
5.2.4.1.2. Prevents infection along with serving other purposes
5.2.4.1.3. Agents used to coat the catheters have already been tested
5.2.4.1.4. New developments give increased mobility
5.2.4.2. Restraints
5.2.4.2.1. Following guidelines for use of uncoated catheters eliminates need for coated ones
5.2.4.2.2. Increasing minimally invasive surgeries
5.2.5. NEURODEGENERATIVE DISEASES
5.2.5.1. Drivers
5.2.5.1.1. New opportunities
5.2.5.1.2. Large segment of population afflicted with the disease
5.3. UROLOGICAL TREATMENTS
5.3.1. DRIVERS
5.3.1.1. Wide array of applications
5.3.1.2. Various factors boost the market
5.3.1.3. Improved efficiency of new treatments
5.3.2. RESTRAINTS
5.3.2.1. Urological diseases overshadowed by cardiovascular diseases
5.3.3. DIALYSIS
5.3.3.1. Drivers
5.3.3.1.1. High per capita revenue
5.3.3.1.2. Reimbursement plans activated
5.3.3.1.3. Convenience associated with home dialysis
5.3.3.2. Restraints
5.3.4. URINARY TRACT INFECTIONS
5.3.4.1. Drivers
5.3.4.1.1. Women prone to such infections
5.3.4.1.2. Prevention better than cure
5.3.4.2. Restraints
5.3.4.2.1. Diagnosing urinary tract infections is still an issue
5.4. BONE TREATMENT
5.4.1. DRIVERS
5.4.1.1. High success ratio to drive the market
5.4.1.2. Degenerative diseases to push the market forward
5.4.1.3. Several factors are promoting their usage
5.4.1.4. Transmission of fatal diseases can be avoided
5.4.2. RESTRAINTS
5.4.2.1. Therapies are not of the same standard as allograft and autografts
5.4.3. JOINT ARTHROPLASTY
5.4.3.1. Drivers
5.4.3.1.1. Deep prosthetics infections reduced to 1.6% from 6%
5.4.3.1.2. Obesity increasing the demand for joint arthroplasty
5.4.3.1.3. Improved accuracy gives confidence to its application
5.4.3.2. Restraints
5.4.3.2.1. Rising necessity of revision surgeries
5.4.4. SPINE FUSION
5.5. ANTIMICROBIAL APPLICATIONS
5.5.1. DRIVERS
5.5.1.1. Application is increasing over time
5.5.1.2. Rising number of diabetic patients
5.5.1.3. Infection prevention leads to faster recovery
5.5.1.4. Reduced expenditure incurred by hospitals
5.5.2. RESTRAINTS
5.5.2.1. Lack of resources in urban safety-net hospitals
5.5.2.2. Developing countries have not adopted these treatments
5.5.3. WOUND CARE
5.5.3.1. Drivers
5.5.3.1.1. Several factors giving boost to the market
5.5.3.1.2. Slowing down in demand is not possible
5.5.3.2. Restraints
5.5.4. SKIN SUBSTITUTES
5.5.4.1. Drivers
5.5.4.1.1. Infection risk is eliminated
5.5.4.1.2. Faster healing reduces period of convalescence
5.5.4.2. Restraints
5.5.4.2.1. Reimbursement issue is a restraining factor
5.6. CANCER TREATMENT
5.6.1. DRIVERS
5.6.1.1. Increase in the number of cancer patients
5.6.1.2. Treatment using PDT is non invasive and patient friendly
5.6.1.3. Risks associated with the treatment is minimal
5.6.1.4. Treatment without risk of side effects
5.6.2. RESTRAINTS
5.6.2.1. Limited applications
5.6.2.2. Possibility of inadequate number of health care professionals
5.6.2.3. New pharmaceutical inventions
5.6.3. BARRETT’S ESOPHAGUS
5.6.3.1. Drivers
5.6.3.1.1. Increasing prevalence of the disease
5.6.3.1.2. Several advantages of the treatment
5.6.3.2. Restraints
5.6.3.2.1. Improved efficiency of the treatment
5.6.4. SKIN CANCER
5.6.4.1. Drivers
5.6.4.1.1. Increased diagnosis of skin cancer cases will give a boost to the market
5.6.4.1.2. Broadening variety of cancer patients
5.6.4.1.3. Prevalence of such cancer in developed countries
5.6.4.1.4. Application not limited to one disease
5.6.4.2. Restraints
5.6.4.2.1. Phototoxicity
5.6.4.2.2. Limited market potential
5.6.5. HEAD AND NECK CANCER
5.6.5.1. Drivers
5.6.5.1.1. Preferred treatment in certain cases
5.6.5.1.2. Less risk of long term infections
5.6.5.2. Restraints
5.6.5.2.1. Patients revert to conventional treatments if cancer relapses
5.6.5.2.2. Low success rate due to co morbidity
5.7. SKIN CARE/TREATMENT
5.7.1. DRIVERS
5.7.1.1. Increasing demand for skin care therapy
5.7.1.2. Treatment is done at the inner dermis layer
5.7.2. RESTRAINTS
5.7.2.1. Loyal customers of cosmetic companies
5.7.2.2. Limited marketing activities for PDT
5.7.3. OPPORTUNITIES
5.7.3.1. Improved marketing activities
5.7.3.2. Untapped potential in developing countries
5.7.4. ACTINIC KERATOSES
5.7.4.1. Drivers
5.7.4.1.1. High demand in the U.S. and Australia
5.7.4.1.2. Enhanced treatment
5.7.4.1.3. Elimination of risk of skin cancer
5.7.4.1.4. Added advantage of cosmetic enhancement
5.7.4.2. Restraints
5.7.4.2.1. Demand is not global
5.7.4.2.2. Repeated procedures make the patients photosensitive
5.7.5. PHOTOREJUVENATION
5.8. OPHTHALMIC TREATMENT
5.8.1. DRIVERS
5.8.1.1. Increased demand from the ageing population
5.8.1.2. Offers physical and economical advantages
5.8.2. RESTRAINTS
5.8.2.1. Repeated treatments required
5.8.3. PATHOLOGIC MYOPIA
5.8.3.1. Drivers
5.8.3.1.1. One of the leading causes of blindness in people of certain races
5.8.3.1.2. Photodynamic therapy is an alternative option
5.8.3.1.3. Increased preference by sportspersons
5.8.3.2. Restraints
5.8.3.2.1. Repetetionof procedures will add to the cost
5.8.3.2.2. Preference of contact lenses over PDT
5.8.4. AGE RELATED MACULAR DEGENERATION
5.8.4.1. Drivers
5.8.4.1.1. Age related macular degeneration has the potential of becoming a national health issue
5.8.4.1.2. Non invasive nature leads to no pain and inconvenience
5.8.4.1.3. No damage to the retina
5.8.4.2. Restraints
5.8.4.2.1. Success restricted by certain factors
5.8.4.2.2. Non recovery of normal 6/6 vision
5.8.5. PRESUMED OCULAR HISTOPLASMOSIS
5.9. DIABETES TREATMENT
5.9.1. DRIVERS
5.9.1.1. Increasing number of diabetes patients
5.9.1.2. Potential in middle income countries
5.9.1.3. New generation treatments effective in diabetic patients
5.9.2. RESTRAINTS
5.9.2.1. Possible restraining factors in future
5.9.2.2. Limited opportunity in Africa
5.9.3. OPPORTUNITIES
5.9.3.1. Obesity and increasing age of people
5.9.3.2. Development in technologies will reduce the cost
6. DRUG-DEVICE COMBINATION MARKET BY TECHNOLOGY
6.1. SYNTHETIC BONE GRAFT SUBSTITUTES
6.1.1. DRIVERS
6.1.1.1. Availability of several types enables customized usage
6.1.1.2. Surgeons have several options
6.1.1.3. Applicable in load bearing body parts
6.1.1.4. Foreign substance eliminated from the body
6.1.1.5. Increased applications
6.1.2. RESTRAINTS
6.1.2.1. Do not possess ideal properties
6.1.2.2. Possible stunted growth in future
6.2. DEMINERALIZED BONE MATRIX
6.2.1. DRIVER
6.2.1.1. Easy to understand technology
6.2.1.2. Applicable for different types of bone defects
6.2.1.3. Growing number of aged people
6.2.2. RESTRAINTS
6.2.2.1. Lack of osteoinductive properties
6.2.2.2. Competition from other procedures
6.3. BONE MORPHOGENIC PROTEINS
7. GEOGRAPHY ANALYSIS
7.1. THE U.S. DRUG-DEVICE COMBINATION MARKET
7.2. THE EUROPEAN DRUG-DEVICE COMBINATION MARKET
7.3. THE ASIAN DRUG DEVICE COMBINATION MARKET
8. COMPANY PROFILES
8.1. INTEGRA LIFESCIENCES HOLDINGS CORP
8.2. SMITH & NEPHEW PLC
8.3. ANGIOTECH PHARMACEUTICALS, INC
8.4. 3M
8.5. ABBOTT LABORATORIES
8.6. ACRYMED
8.7. ALLOSOURCE
8.8. LIFECELL CORP
8.9. NUCRYST PHARMACEUTICALS, INC
8.10. ORBUSNEICH CO., LTD
8.11. ORGANOGENESIS, INC
8.12. OSTEOTECH, INC
8.13. FORTICELL BIOSCIENCE, INC
8.14. SPIRE BIOMEDICAL INC
8.15. ST. JUDE MEDICAL INC
8.16. AGION TECHNOLOGIES, INC
8.17. APATECH
8.18. BIOMET ORTHOPEDICS, INC
8.19. BIOSENSORS
8.20. BIOTRONIK
8.21. C.R. BARD, INC
8.22. KIADIS PHARMA B.V
8.23. CORIN
8.24. COVALON
8.25. COVIDIEN LTD
8.26. DUSA PHARMACEUTICALS, INC.
8.27. DEPUY ORTHOPAEDICS INC
8.28. EDWARDS LIFESCIENCES CORP
8.29. ETEX
8.30. ETHICON, INC.
8.31. EXACTECH INC.
8.32. STRYKER CORPORATION
8.33. DAVOL INC.
8.34. SUNGWON MEDICAL CO., LTD
8.35. TEI BIOSCIENCES, INC.
8.36. VYGON S.A
8.37. W.L. GORE & ASSOCIATES INC.
8.38. WRIGHT MEDICAL GROUP, INC.
8.39. XTENT
8.40. COLLAGEN MATRIX, INC.
8.41. COOK CRITICAL CARE, INC.
8.42. ARROW INTERNATIONAL
8.43. BIOMETRIX MEDICAL
8.44. ZIMMER HOLDING, INC.
8.45. MEDTRONIC, INC.
8.46. QLT INC.
8.47. COOK MEDICAL
8.48. BOSTON SCIENTIFIC CORPORATION
8.49. ATRIUM MEDICAL CORPORATION
8.50. CORDIS CORPORATION
8.51. SYNTHES, INC.
9. PATENT ANALYSIS
9.1. U.S. PATENTS
9.2. E.U. PATENTS
9.3. ASIA PATENTS
APPENDIX
LIST OF FIGURES
FIGURE 1 PARENTAL STRUCTURE OF DRUG-COMBINATION MARKET
FIGURE 2 EVOLUTION OF DRUG-DEVICE COMBINATION
FIGURE 3 FACTORS AFFECTING THE DRUG-DEVICE COMBINATION MARKET
FIGURE 4 CURRENT FAVORABILITY FOR DRUG-DEVICE COMBINATION MARKET
FIGURE 5 MARKET POTENTIAL FOR DRUG-DEVICE COMBINATION MARKET
FIGURE 6 TRENDS IN R&D FOR DRUG-DEVICE COMBINATION MARKET
FIGURE 7 GLOBAL MARKET SHARE OF KEY PLAYERS
FIGURE 8 GLOBAL SEGMENTATION OF DRUG-DEVICE COMBINATION PATENTS
LIST OF TABLES
SUMMARY TABLE GLOBAL DRUG DEVICE COMBINATION MARKET 2007 – 2014 ($MILLIONS)
TABLE 1 GLOBAL ANTIMICROBIAL CATHETER MARKET, BY PRODUCTS 2007 – 2014 ($ MILLIONS)
TABLE 2 GLOBAL ANTIMICROBIAL CATHETER MARKET, BY GEOGRAPHY 2007 – 2014 ($MILLIONS)
TABLE 3 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 4 GLOBAL UROLOGICAL CATHETER MARKET, BY PRODUCTS 2007 – 2014 ($ MILLIONS)
TABLE 5 GLOBAL UROLOGICAL CATHETER MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 6 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 7 GLOBAL DIALYSIS CATHETER MARKET, BY PRODUCTS 2007 – 2014 ($ MILLIONS)
TABLE 8 GLOBAL DIALYSIS CATHETER MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 9 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 10 GLOBAL HEMODIALYSIS CATHETER MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 11 GLOBAL PERITONEAL CATHETER MARKET, BY GEOGRAPHY, 2007 – 2014 ($ MILLIONS)
TABLE 12 GLOBAL URINARY CATHETER MARKET, BY PRODUCTS 2007 – 2014 ($ MILLIONS)
TABLE 13 GLOBAL URINARY CATHETER MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 14 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 15 GLOBAL INDWELLING CATHETER MARKET, BY GEOGRPHY 2007 – 2014 ($ MILLIONS)
TABLE 16 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 17 GLOBAL EXTERNAL CATHETER MARKET, BY GOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 18 GLOBAL OXIMETRY CATHETER MARKET, BY PRODUCTS 2007 – 2014 ($ MILLIONS)
TABLE 19 GLOBAL THERMODILUTION CATHETER MARKET BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 20 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 21 GLOBAL ADVANCED WOUND CARE PRODUCTS MARKET, BY PRODUCTS 2007 – 2014 ($ MILLIONS)
TABLE 22 GLOBAL ADVANCED WOUND CARE PRODUCTS MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 23 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 24 GLOBAL ANTIBIOTIC WOUND CARE MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 25 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 26 GLOBAL BONE GRAFT SUBSTITUES MARKET, BY PRODUCTS 2007 – 2014 ($ MILLIONS)
TABLE 27 GLOBAL BONE GRAFT SUBSTITUES MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 28 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 29 GLOBAL CERAMIC BASED BONE GRAFT SUBSTITUTES MARKET, BY PRODUCTS 2007 – 2014 ($ MILLIONS) .
TABLE 30 GLOBAL CERAMIC BASED BONE GRAFT SUBSTITUTES MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 31 GLOBAL CERAMIC BASED BONE GRAFT SUBSTITUTES MIXED WITH CALCIUM PHOSPHATE MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 32 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 33 GLOBAL ALLOGRAFT BASED BONE GRAFT SUBSTITUTES MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 34 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 35 GLOBAL FACTORS BASED BONE GRAFT SUBSTITUTES, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 36 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 37 GLOBAL CELL BASED BONE GRAFT SUBSTITUTES MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 38 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 39 GLOBAL ANTIBIOTIC BONE CEMENTS MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 40 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 41 GLOBAL DRUG ELUTING STENTS MARKET, BY PRODUCTS 2007 – 2014 ($ MILLIONS)
TABLE 42 GLOBAL DRUG ELUTING STENTS MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 43 GLOBAL CORONARY STENTS MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 44 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 45 GLOBAL PERIPHERAL VASCULAR STENT MARKET BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 46 GLOBAL PHOTODYNAMIC THERAPY MARKET, BY PRODUCTS 2007 – 2014 ($ MILLIONS)
TABLE 47 GLOBAL PHOTODYNAMIC THERAPY MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 48 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 49 GLOBAL AMINOLEVULINIC ACID MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 50 GLOBAL PORFIMER SODIUM MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS) .
TABLE 51 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 52 GLOBAL VERTEPORFIN MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 53 GLOBAL STEROID ELUTING ELECTRODES MARKET BY PRODUCTS 2007 – 2014 ($ MILLIONS)
TABLE 54 GLOBAL STEROID ELUTING ELECTRODES MARKET BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 55 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 56 GLOBAL IMPLANTABLE CARDIOVERTER MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 57 GLOBAL DEEP BRAIN STIMULATOR MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 58 GLOBAL CLOSED LOOP GLUCOSE MONITOR AND INSULIN PUMP MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 59 MAJOR PLAYERS AND PRODUCT DEVELOPMENTS
TABLE 60 GLOBAL CARDIOVASULAR TREATMENT MARKET, BY APPLICATION 2007 – 2014 ($ MILLIONS)
TABLE 61 GLOBAL NON CARDIOVASCULAR TREATMENT MARKET, BY APPLICATION 2007 – 2014 ($ MILLIONS)
TABLE 62 GLOBAL UROLOGICALTREATMENT MARKET, BY APPLICATION 2007 – 2014 ($ MILLIONS)
TABLE 63 GLOBAL BONE TREATMENT MARKET, BY APPLICATION 2007 – 2014 ($ MILLIONS)
TABLE 65 GLOBAL CANCER TREATMENT MARKET, BY APPLICATION 2007 – 2014 ($ MILLIONS) TABLE 66 GLOBAL SKIN CARE/TREATMENT MARKET, BY APPLICATION 2007 – 2014 ($ MILLIONS)
TABLE 67 GLOBAL OPHTHALMIC TRETMENT MARKET, BY APPLICATION 2007 – 2014 ($ MILLIONS) TABLE 68 GLOBAL BONE GRAFT SUBSTITUTES MARKET, BY TECHNOLOGY 2007 – 2014 ($ MILLIONS) TABLE 69 GLOBAL DRUG-DEVICE COMBINATION MARKET 2007 – 2014 ($ MILLIONS)
TABLE 70 U.S. DRUG-DEVICE COMBINATION MARKET 2007 – 2014 ($ MILLIONS)
TABLE 71 EUROPEAN DRUG-DEVICE COMBINATION MARKET 2007 – 2014 ($ MILLIONS)
TABLE 72 ASIAN DRUG-DEVICE COMBINATION MARKET 2007 – 2014 ($ MILLIONS)
TABLE 73 INTEGRA LIFESCIENCES PRODUCT PORTFOLIO
TABLE 74 INTEGRA LIFESCIENCES STRATEGIES
TABLE 75 SMITH & NEPHEW’S PRODUCT PORTFOLIO
TABLE 76 SMITH & NEPHEW STRATEGIES
TABLE 77 ANGIOTECH PHARMACEUTICALS’ PRODUCT PORTFOLIO
TABLE 78 ANGIOTECH PHARMACEUTICALS STRATEGIES
TABLE 79 3M’S PRODUCT PORTFOLIO
TABLE 80 3M STRATEGIES
TABLE 81 ABBOTT LABORATORIES’ PRODUCT PORTFOLIO
TABLE 82 ABBOTT LABORATORIES STRATEGIES
TABLE 83 ACRYMED’S PRODUCT PORTFOLIO
TABLE 84 ALLOSOURCE’S PRODUCT PORTFOLIO
TABLE 85 ALLOSOURCE STRATEGIES
TABLE 86 LIFECELL CORP.’S PRODUCT PORTFOLIO
TABLE 87 NUCRYST PHARMACEUTICALS PRODUCT PORTFOLIO
TABLE 88 ORBUSNEICH CO., LTD. PRODUCT PORTFOLIO
TABLE 89 ORGANOGENESIS, INC’S PRODUCT PORTFOLIO
TABLE 90 OSTEOTECH, INC.’S PRODUCT PORTFOLIO
TABLE 91 SPIRE BIOMEDICAL’S PRODUCT PORTFOLIO
TABLE 92 ST. JUDE’S PRODUCT PORTFOLIO
TABLE 93 ST. JUDE STRATEGIES
TABLE 94 AGION TECHNOLOGIES PRODUCT PORTFOLIO
TABLE 95 AGION TECHNOLOGIES, INC. STRATEGIES
TABLE 96 APATECH’S PRODUCT PORTFOLIO
TABLE 97 BIOMET ORTHOPEDICS’ PRODUCT PORTFOLIO
TABLE 98 BIOSENSORS’ PRODUCT PORTFOLIO
TABLE 99 BIOSENSORS STRATEGIES
TABLE 100 BIOTRONIK’S PRODUCT PORTFOLIO
TABLE 101 BIOTRONIK STRATEGIES
TABLE 102 C.R. BARD’S PRODUCT PORTFOLIO
TABLE 103 BIOTRONIK STRATEGIES
TABLE 104 KIADIS PHARMA’S PRODUCT PORTFOLIO
TABLE 105 CORIN PRODUCT PORTFOLIO
TABLE 106 CORIN STRATEGIES
TABLE 107 COVALON’S PRODUCT PORTFOLIO
TABLE 108 COVALON STRATEGIES
TABLE 109 COVIDIEN’S PRODUCT PORTFOLIO
TABLE 110 COVIDIEN STRATEGIES
TABLE 111 DUSA PHARMACEUTICALS’ PRODUCT PORTFOLIO
TABLE 112 DUSA PHARMACEUTICALS STRATEGIES
TABLE 113 DEPUY ORTHOPAEDICS’ PRODUCT PORTFOLIO
TABLE 114 EDWARDS LIFESCIENCES PRODUCT PORTFOLIO
TABLE 115 ETEX’S PRODUCT PORTFOLIO
TABLE 116 ETEX STRATEGIES
TABLE 117 ETHICON’S PRODUCT PORTFOLIO
TABLE 118 EXACTECH’S PRODUCT PORTFOLIO
TABLE 119 STRYKER’S PRODUCT PORTFOLIO
TABLE 120 DAVOL’S PRODUCT PORTFOLIO
TABLE 121 SUNGWON’S MEDICAL PRODUCT PORTFOLIO
TABLE 122 TEI BIOSCIENCES PRODUCT PORTFOLIO
TABLE 123 VYGON’S PRODUCT PORTFOLIO
TABLE 124 W.L. GORE & ASSOCIATES PRODUCT PORTFOLIO
TABLE 125 W.L. GORE & ASSOCIATES STRATEGIES
TABLE 126 WRIGHT MEDICAL’S PRODUCT PORTFOLIO
TABLE 127 XTENT’S PRODUCT PORTFOLIO
TABLE 128 COLLAGEN’S MATRIX PRODUCT PORTFOLIO
TABLE 129 COOK CRITICAL CARE’S PRODUCT PORTFOLIO
TABLE 130 ARROW INTERNATIONAL’S PRODUCT PORTFOLIO
TABLE 131 BIOMETRIX’S PRODUCT PORTFOLIO
TABLE 132 ZIMMER’S PRODUCT PORTFOLIO
TABLE 133 ZIMMER STRATEGIES
TABLE 134 MEDTRONIC’S PRODUCT PORTFOLIO
TABLE 135 MEDTRONIC STRATEGIES
TABLE 136 QLT’S PRODUCT PORTFOLIO
TABLE 137 COOK MEDICAL’S PRODUCT PORTFOLIO
TABLE 138 COOK MEDICAL STRATEGIES
TABLE 139 BOSTON SCIENTIFIC’S PRODUCT PORTFOLIO
TABLE 140 BOSTON SCIENTIFIC STRATEGIES
TABLE 141 ATRIUM MEDICAL’S PRODUCT PORTFOLIO
TABLE 142 ATRIUM MEDICAL STRATEGIES
TABLE 143 CORDIS CORPORATION’S PRODUCT PORTFOLIO
TABLE 144 SYNTHES PRODUCT PORTFOLIO
